ATLANTA -- Maintenance treatment with the PARP inhibitor rucaparib (Rubraca) was well tolerated and provided clinical responses among patients with ...
ATLANTA -- The investigational anticancer therapeutic LOXO-195 (now known as BAY 2731954), which targets a family of proteins called TRKs, ...
Fate Therapeutics, in collaboration with UC San Diego researcher, developed first off-the-shelf immunotherapy from human induced pluripotent stem cells that ...
Credit: University of Colorado Cancer Center A study by University of Colorado Cancer Center and Rain Therapeutics, Inc. presented at ...
Credit: Mary Ann Liebert, Inc., publishers New Rochelle, NY, April 1, 2019--Modern medicines have positively contributed to public health and ...
Credit: University of Colorado Cancer Center A cancer cell is like a racecar, speeding through the process of cellular replication. ...
Credit: University of Colorado Cancer Center Many cancers are relatively harmless at their site of origin, and it is only ...
Rehab gloveCredit: UT Arlington The University of Texas at Arlington Research Institute is making flexible soft robotic gloves that will ...
ATLANTA -- A combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the anti-PD-1 therapeutic pembrolizumab (Keytruda) showed clinical ...
Metformin can halve the risk of late miscarriage and preterm births for women with polycystic ovary syndrome (PCOS). PCOS occurs ...
ATLANTA -- Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory acute myeloid leukemia ...
ATLANTA -- The investigational therapeutic umbralisib, which targets the molecule PI3K-delta, was well tolerated and highly active in patients with ...
ATLANTA -- The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumor activity with durable responses in patients with pretreated, advanced ...
Credit: Hope Foundation for Cancer Research A combination of two common immunotherapy drugs shrinks rare, aggressive neuroendocrine tumors, according to ...
